EP Biocomposites Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1003694,
    "name": "EP Biocomposites",
    "stock_name": "EP Biocomposites",
    "full_name": "EP Biocomposites Ltd",
    "name_url": "stocks-analysis/ep-biocomposites",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "98.00",
    "chg": "0.00",
    "chgp": "0.00%",
    "dir": 0,
    "prev_price": "98.00",
    "mcapval": "17.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 543595,
    "symbol": "",
    "ind_name": "Other Utilities",
    "ind_code": 67,
    "indexname": "",
    "isin": "INE0D2I01014",
    "curr_date": "Jan 30",
    "curr_time": "",
    "bse_nse_vol": 1000,
    "exc_status": "Active",
    "traded_date": "Jan 30, 2026",
    "traded_date_str": "2026 01 30",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/ep-biocomposites-1003694-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is EP Biocomposites overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-ep-biocomposites-overvalued-or-undervalued-3716787",
        "imagepath": "",
        "date": "2025-11-20 08:07:30",
        "description": "As of 19 November 2025, EP Biocomposites has moved from a fair valuation to an expensive rating. The company is currently considered overvalued based on its financial metrics. Key ratios include a PE ratio of 15.35, an EV to EBIT of 11.15, and a ROCE of 12.38%. \n\nIn comparison to its peers, EP Biocomposites' PE ratio is significantly lower than that of Altius Telecom, which has a PE of 51.84, indicating that EP Biocomposites is not positioned favorably within its industry. Additionally, the company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -45.03% compared to the Sensex's 9.02%, further reinforcing the notion that the stock is overvalued...."
      },
      {
        "title": "Is EP Biocomposites overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-ep-biocomposites-overvalued-or-undervalued-3709968",
        "imagepath": "",
        "date": "2025-11-18 08:25:50",
        "description": "As of 17 November 2025, the valuation grade for EP Biocomposites has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 15.35, an EV to EBIT of 11.15, and an ROCE of 12.38%. \n\nIn comparison to peers, EP Biocomposites has a similar valuation to Sagility, which is also rated fair with a PE of 29.82, but significantly lower than Altius Telecom, which is rated very attractive with a PE of 51.5. Notably, EP Biocomposites has seen a substantial decline in stock performance, with a year-to-date return of -45.03%, contrasting sharply with the Sensex's gain of 8.72% during the same period...."
      },
      {
        "title": "Is EP Biocomposites overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-ep-biocomposites-overvalued-or-undervalued-3687794",
        "imagepath": "",
        "date": "2025-11-11 08:14:03",
        "description": "As of 10 November 2025, the valuation grade for EP Biocomposites has moved from very expensive to expensive. The company is currently considered overvalued. Key ratios include a PE Ratio of 17.14, an EV to EBITDA of 11.50, and a Price to Book Value of 1.65. In comparison, Altius Telecom, which is rated very attractive, has a significantly higher PE Ratio of 56.22, while Sagility, rated fair, has a PE Ratio of 29.75.\n\nThe recent performance of EP Biocomposites has been notably poor, with a year-to-date stock return of -38.6%, contrasting sharply with a Sensex return of 6.91% over the same period. This underperformance further supports the conclusion that the company is overvalued relative to its peers and the broader market...."
      }
    ],
    "total": 62,
    "sid": "1003694",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/ep-biocomposites-1003694"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order",
      "datetime": "22-Jan-2026",
      "details": "Intimation of receiving new work order for 1000 units of Model IV Premium Cast Iron Benches amounting to INR 21500000",
      "source": "BSE"
    },
    {
      "caption": "Financial Results For The Half Year Ended September 30 2025",
      "datetime": "03-Nov-2025",
      "details": "Financial results for the half year ended September 30 2025",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of The Board Meeting- Financial Results For The Half Year Ended September 30 2025",
      "datetime": "03-Nov-2025",
      "details": "Outcome of the Board Meeting- Financial results for the half year ended September 30 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Is EP Biocomposites overvalued or undervalued?

2025-11-20 08:07:30

As of 19 November 2025, EP Biocomposites has moved from a fair valuation to an expensive rating. The company is currently considered overvalued based on its financial metrics. Key ratios include a PE ratio of 15.35, an EV to EBIT of 11.15, and a ROCE of 12.38%. In comparison to its peers, EP Biocomposites' PE ratio is significantly lower than that of Altius Telecom, which has a PE of 51.84, indicating that EP Biocomposites is not positioned favorably within its industry. Additionally, the company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -45.03% compared to the Sensex's 9.02%, further reinforcing the notion that the stock is overvalued....

Is EP Biocomposites overvalued or undervalued?

2025-11-18 08:25:50

As of 17 November 2025, the valuation grade for EP Biocomposites has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 15.35, an EV to EBIT of 11.15, and an ROCE of 12.38%. In comparison to peers, EP Biocomposites has a similar valuation to Sagility, which is also rated fair with a PE of 29.82, but significantly lower than Altius Telecom, which is rated very attractive with a PE of 51.5. Notably, EP Biocomposites has seen a substantial decline in stock performance, with a year-to-date return of -45.03%, contrasting sharply with the Sensex's gain of 8.72% during the same period....

Is EP Biocomposites overvalued or undervalued?

2025-11-11 08:14:03

As of 10 November 2025, the valuation grade for EP Biocomposites has moved from very expensive to expensive. The company is currently considered overvalued. Key ratios include a PE Ratio of 17.14, an EV to EBITDA of 11.50, and a Price to Book Value of 1.65. In comparison, Altius Telecom, which is rated very attractive, has a significantly higher PE Ratio of 56.22, while Sagility, rated fair, has a PE Ratio of 29.75. The recent performance of EP Biocomposites has been notably poor, with a year-to-date stock return of -38.6%, contrasting sharply with a Sensex return of 6.91% over the same period. This underperformance further supports the conclusion that the company is overvalued relative to its peers and the broader market....

View All News